Hua Medicine Ltd. is a biotechnology company specializing in the development and commercialization of innovative drug therapies, primarily targeting diabetes and related metabolic diseases. Headquarte... Hua Medicine Ltd. is a biotechnology company specializing in the development and commercialization of innovative drug therapies, primarily targeting diabetes and related metabolic diseases. Headquartered in Shanghai, the company leverages global resources and collaborations to address unmet medical needs worldwide. Its flagship product, dorzagliatin, is an oral treatment designed to regulate glucose homeostasis in patients with Type 2 diabetes by activating glucokinase, the glucose sensor in the body. This unique therapeutic approach aims to restore natural insulin secretion and improve overall glucose control, particularly benefiting individuals with impaired renal function. Hua Medicine's research-driven pipeline emphasizes cutting-edge pharmaceutical solutions, contributing to advancements in diabetes care and signaling China's growing influence in global pharmaceutical innovation. Beyond its core focus, the company continually explores new therapeutic fields and market opportunities to expand its impact within the healthcare sector.
Pending data availability
Climate Targets Data missing for Hua Medicine
We haven’t collected Climate Targets data for Hua Medicine yet, or the company
hasn’t made it publicly available.